Most Popular
-
1
Korea’s homegrown nanosatellite successfully launches into space
-
2
[Herald Interview] 'Amid aging population, Korea to invite more young professionals from overseas'
![[Herald Interview] 'Amid aging population, Korea to invite more young professionals from overseas'](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/04/24/20240424050844_0.jpg&u=20240424200058)
-
3
Nicaragua shuts down Seoul embassy
-
4
Hybe's multilabel system tested amid conflict with Ador
-
5
Rocket engine expert, ex-NASA exec to lead Korea's new space agency
![[Herald Interview] 'Amid aging population, Korea to invite more young professionals from overseas'](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/04/24/20240424050844_0.jpg&u=20240424200058)
-
6
SNU profs to suspend treatment for one day
-
7
SK hynix pledges W20tr to ramp up DRAM production at home
-
8
Over-50s, men, single-person households take up majority of those filing for bankruptcy
-
9
Ministry denies blame for Jamboree debacle
-
10
Pianist Cho Seong-Jin named Berlin Philharmonic's artist-in-residence
[THE INVESTOR] NH Investment & Securities maintained a “buy” rating for Celltrion on Aug. 10, saying that the biopharma firm has met expectations in its second-quarter performance.
The company reported on Aug. 9 that its operating profit decreased 5.7 percent to 75.2 billion won (US$68.78 million) and sales increased 7.4 percent to 159.9 billion won from the same period last year.
“The revenue has grown as prescriptions for (its first antibody biosimilar) Remsima increased in Europe while the operating profit fell as it reflected 15.7 billion won spent in R&D,” said Lee Seung-ho, an analyst at NH.
“There is a possibility that it will release Remsima in the US on Oct. 3.”
By Hwang You-mee (glamazon@heraldcorp.com)
The company reported on Aug. 9 that its operating profit decreased 5.7 percent to 75.2 billion won (US$68.78 million) and sales increased 7.4 percent to 159.9 billion won from the same period last year.
“The revenue has grown as prescriptions for (its first antibody biosimilar) Remsima increased in Europe while the operating profit fell as it reflected 15.7 billion won spent in R&D,” said Lee Seung-ho, an analyst at NH.
“There is a possibility that it will release Remsima in the US on Oct. 3.”
By Hwang You-mee (glamazon@heraldcorp.com)
![[KH Explains] Korean shipbuilding stocks rally: Real growth or bubble?](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=652&simg=/content/image/2024/04/25/20240425050656_0.jpg&u=)
